Effects of Darbepoetin Alfa on Plasma Mediators of Oxidative and Nitrosative Stress in Anemic Patients With Chronic Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy

American Journal of Cardiology

Volumn 103, Issue 8, 2009, Pages 1134-1138

  Parissis, John T ^a   Kourea, Kallirrhoe ^a   Andreadou, Ioanna ^b   Ikonomidis, Ignatios ^a   Markantonis, Sophia ^b   Ioannidis, Konstadinos ^b   Paraskevaidis, Ioannis ^a   Iliodromitis, Efstathios ^a   Filippatos, Gerasimos ^a   Kremastinos, Dimitrios Th ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARBONYL DERIVATIVE; CREATININE; GLUTATHIONE; HEMOGLOBIN; IRON; MALONALDEHYDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXIDIZING AGENT; PLACEBO;

AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; MEDIATOR; NITROSATIVE STRESS; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME; WALKING;

AGED; ANEMIA; CARDIOMYOPATHIES; CHRONIC DISEASE; ERYTHROPOIETIN; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; NITROSATION; OXIDATIVE STRESS;

EID: 63749084132     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.12.041     Document Type: Article

References (30)

1. Keith M., Geranmayegan A., Sole M.J., Kurian R., Robinson A., Omran A.S., and Jeejeebhoy K.N. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 31 (1998) 1352-1356
2. Pacher P., Schulz R., Liaude L., and Szabo C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 26 (2005) 302-310
3. Adamopoulos S., Parissis J., and Kremastinos D. Endothelial dysfunction in chronic heart failure: clinical and therapeutic implications. Eur J Intern Med 13 (2002) 233-239
4. Ferrari R., Guardigli G., Mele D., Percoco G.F., Ceconi C., and Curello S. Oxidative stress during myocardial ischemia and heart failure. Curr Pharm Des 10 (2004) 1699-1711
5. Turko I.V., and Murad F. Protein nitration in cardiovascular diseases. Pharmacol Rev 54 (2002) 619-634
6. Anand I. Anemia and chronic heart failure: implications and treatment options. J Am Coll Cardiol 52 (2008) 501-511
7. Li Y., Takemura G., Okada H., Miyata S., Maruyama R., Li L., Higuchi M., Minatoguchi S., Fujiwara T., and Fujiwara H. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 71 (2006) 684-694
8. Silverberg D.S., Wexler D., Sheps D., Blum M., Keren G., Baruch R., Schwartz D., Yachnin T., Steinbruch S., Shapira I., Laniado S., and Iaina A. The effect of correction of mild anemia in severe, resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 (2001) 1775-1780
9. Silverberg D.S., Wexler D., Blum B., Keren G., Sheps D., Leibovitch E., Brosh D., Laniado S., Schwartz D., Yachnin T., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 (2000) 1737-1744
10. Palazzuoli A., Silverberg D., Iovine F., Calabro A., Campagna M., Gallotta M., and Nuti R. Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 154 (2007) 645e9-645e15
11. Parissis J., Kourea K., Panou F., Farmakis D., Paraskevaidis I., Ikonomidis I., Filippatos G., and Kremastinos D.T. Effects of darbepoetin-alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 155 (2008) 751e1-751e7
12. Kourea K., Parissis J., Farmakis D., Panou F., Paraskevaidis I., Venetsanou K., Filippatos G., and Kremastinos D.T. Effects of darbepoetin-α on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerosis 199 (2008) 215-221
13. Henry D., Bowers P., Romano M., and Provenzano R. Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch Intern Med 164 (2004) 262-276
14. Cleland J., Sullivan J., Ball S., Horowitz J.D., Agoram B., Rosser D., Yates W., Tin L., Fuentealba P., and Burton P.B. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol 46 (2005) 155-161
15. Vansteenkiste J. Every 3 weeks dosing with darbepoetin alfa: a new paradigm in anaemia management. Cancer Treat Rev 32 suppl 2 (2006) S11-S15
16. Parissis J., Andreadou I., Markantonis S.I., Bistola V., Louka A., Pyriochou A., Paraskevaidis I., Filippatos G., Iliodromitis E.K., and Kremastinos D.T. Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis 195 (2007) e210-e215
17. Esterbauer H., and Cheeseman K. Determination of aldehydic lipid peroxidation products: malondialdehyde and 4-hydroxy-nonenal. Methods Enzymol 186 (1990) 407-421
18. Sigala F., Theocharis S., Sigalas K., Markantonis-Kyroudis S., Papalabros E., Triantafyllou A., Kostopanagiotou G., and Andreadou I. Therapeutic value of melatonin in an experimental model of liver injury and regeneration. J Pineal Res 40 (2006) 270-279
19. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., Ahn B.W., Shaltiel S., and Stadtman E.R. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186 (1990) 464-478
20. Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B., Thompson R.B., Petrofski J.A., Annex B.H., Stamler J.S., and Koch W.J. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112 (2003) 999-1007
21. Arcasoy M.O. The non-hematopoietic biological effects of erythropoietin. Br J Haematol 141 (2008) 14-31
22. Horl W.H. Adjunctive therapy in anemia management. Nephrol Dial Transplant 17 (2002) 56-59
23. Sommerburg O., Grune T., Hampl H., Riedel E., van Kuijk F.J., Ehrich J.H., and Siems W.G. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients?. Nephrol Dial Transplant 13 (1998) 2583-2587
24. Cameron V., Mocatta T.J., Pilbrow A.P., Frampton C.M., Troughton R.W., Richards A.M., and Winterbourn C.C. Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension 47 (2006) 1155-1161 1129
25. Siems W., Carluccio F., Radenkovic S., Grune T., and Hampl H. Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment. Kidney Blood Press Res 28 (2005) 295-301
26. Campolo J., DeMaria R., Caruso R., Accinni R., Turazza F., Parolini M., Roubina E., De Chiara B., Cighetti G., Frigerio M., Vitali E., and Parodi O. Blood glutathione as independent marker of lipid peroxidation in heart failure. Int J Cardiol 117 (2007) 45-50
27. Ludat K., Sommerburg O., Grune T., Siems W.G., Riedel E., and Hampl H. Oxidation parameters in complete correction of renal anemia. Clin Nephrol 53 suppl (2000) S30-S35
28. Papavasiliou E.C., Gouva C., Siamopoulos K.C., and Tselepis A.D. Erythrocyte PAF acetylhydrolase activity in various stages of chronic kidney disease: effect of long term-therapy with erythropoietin. Kidney Int 68 (2005) 246-255
29. White M., Ducharne A., Ibrahim R., Whittom L., Lavoie J., Guertin M.C., Racine N., He Y., Yao G., Rouleau J.L., Schiffrin E.L., and Touyz R.M. Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clin Sci 110 (2006) 483-489
30. Cuzzocrea S., Mazzon E., diPaola R., Genovese T., Patel N.S., Britti D., de Majo M., Caputi A.P., and Thiemermann C. Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. Arthritis Rheum 52 (2005) 940-950